Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]